London's healthcare company Stallergenes Greer on Friday announced plans to advance precision medicine in AIT (allergen immunotherapy) under a research collaboration with Alyatec, a contract research organisation based in Strasbourg University Hospital, France.
Through this partnership with Alyatec, Stallergenes Greer will strengthen its precision medicine-based approach and the management of patients with allergies by expanding its knowledge of allergy pathophysiology and endotypes, AIT mode of action and clinical validation.
The research collaboration will combine the longstanding expertise of Stallergenes Greer in AIT with Alyatec's competencies in research and clinical services as well as its state-of-the-art technology, including a new generation environmental exposure chamber.
Allergies are reportedly the most prevalent and fastest growing chronic disease in the industrialised world, affecting over one billion people worldwide. Allergen immunotherapy is an allergy treatment designed to alter the natural course of respiratory allergies by treating the underlying cause of the disease. Allergen extracts are modifying disease by inducing tolerance in the immune system.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary